US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ultragenyx Pharmaceutical Inc. - Common Stock
(NQ:
RARE
)
15.30
-0.18 (-1.16%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ultragenyx Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
October 07, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
October 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 29, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 22, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)
September 17, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 15, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 08, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome
September 02, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease
September 01, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
August 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
August 04, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
July 28, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
July 08, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
June 23, 2026
Industry Veteran Brings More Than Three Decades of Biopharmaceutical Development and Clinical Operations Experience to Help Guide Pipeline Advancement
From
Calidi Biotherapeutics, Inc
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 22, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
May 06, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
May 05, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
April 29, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm
April 06, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
April 06, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE
April 03, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
RARE Deadline: Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
April 03, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
ULTRAGENYX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – RARE
April 02, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
April 02, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
